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Abstract
The discovery of heavy-chain-only antibodies (HCAbs) in camelids and sharks led to 
the rise of a new research field in which single-domain antibodies are used for various 
applications. Single-domain antibodies are the antigen-binding fragments derived from 
HCAbs showing several beneficial properties (e.g., small size, specificity, stability under 
extreme conditions, cost-effective production, and ease of engineering). Importantly, they 
are stable in reducing cytoplasmic environment, which allows their use as an intrabody 
to target a wide range of intracellular targets. In this chapter, we discuss both the ther-
apeutic potential of camelid single-domain antibodies (nanobodies) and their use as a 
research tool with the main focus on its intracellular employment. Targeting intracellular 
proteins using nanobodies as a therapeutic per se is, up to now, limited due to its inca-
pacity to traverse the cellular membrane. They can however serve as a stepping stone to 
small compound development, since they directly target a resident, endogenous protein, 
similar to how a conventional drug acts. In addition, nanobodies are highly adaptable 
tools and possess interesting properties for more fundamental research objectives like the 
elucidation of protein function, the tracking and visualization of endogenous proteins in 
an in vivo setting, and the assessment of protein-protein interactions.
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1. Nanobodies: a concise introduction
In 1993, Hamers-Casterman discovered the presence of heavy-chain-only antibodies in the 
sera of Camelidae and assessed that these antibodies are still capable of recognizing an exten-
sive repertoire of antigens despite the absence of the light chain. Single-domain antibodies 
from camels are called nanobodies. They stated that this discovery could be of inestimable 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
value to the development and engineering of soluble VH domains or new immunological mol-
ecules for diagnostic, therapeutic, and biochemical purposes [1]. This discovery gave rise to 
a whole new research field in which single-domain antibodies are used for a wide range of 
applications. Some of these will be reviewed in the current chapter.
The structural properties of conventional IgG antibodies are well known. These consist of 
two heavy-chain polypeptides and two light-chain polypeptides, each of which is folded into 
four and two domains, respectively. A variable domain is situated at the N-terminus of both 
chains (VH and VL) and, as the name suggests, its sequence diverges between IgG antibod-
ies. Paired VH-VL domains make up the variable fragment (Fab) and are responsible for the 
recognition and binding of the target antigen. The sequence of the other domains is well 
conserved between IgGs, which led to the designation of these domains as constant domains. 
Heavy-chain-only antibodies differ from conventional IgG antibodies by the lack of a light-
chain polypeptide and the first constant domain of the heavy-chain polypeptide (CH1). 
Consequently, the antigen-binding fragment of heavy-chain antibodies from camels consists 
of one single domain, termed the VHH domain. This unit forms the functional and structural 
equivalent of the Fab in conventional IgG antibodies [2]. The smallest antibody fragment that 
can be produced from conventional IgG antibodies is a short-chain variable fragment (ScFv, 
±27 kDa), which consists of a VH and VL domain linked via a polypeptide. In the continuous 
search for smaller antibody formats, HCAbs were a thrilling novelty, because their discovery 
allowed researchers to produce an even smaller antibody fragment of only ±15 kDa. This 
antibody format derived from camels consists of an isolated VHH domain also known as a 
single-domain antibody or a nanobody (Nb) (Figure 1). In addition, human single-domain 
antibodies VH and VL have been engineered from human conventional antibodies [3–5], and 
sharks develop heavy-chain-only antibodies (HCAbs) too [6].
The structural features of nanobodies are quite similar to those of the variable domain of 
conventional IgGs. The core structure of the immunoglobulin domain is formed by four 
framework regions (FR), whereas antigen binding occurs through three complementarity-
determining regions (CDRs). The latter are located in loops in between β-strands that form 
the variable immunoglobulin domain. Importantly, FR2 of the VHH domain often contains 
amino acid substitutions of residues that are involved in hydrophobic interactions between 
the VH and the VL domains of conventional IgGs (V37 → F/Y, G44 → E/Q, L45 → R, and 
W47 → G/F/L; Kabat numbering). These substitutions lie at the heart of the single-domain 
nature of nanobodies because they reduce the hydrophobicity of the former VL interface and 
improve the nonstickiness of the domain. There are other examples of amino acid substitutions 
that frequently take place, but these appear to be of less importance [7, 8]. Since nanobodies 
only consist of one domain, one might wonder whether nanobodies have a diverse antibody 
repertoire. After all, they lack the VH-VL combinatorial diversity in the antigen-binding site. 
Nanobodies have counterbalanced the absence of the three hypervariable loops of the VL 
domain by an extension of the hypervariable loops in the VHH domain. These loops show sub-
stantial variation in both conformation and length compared with the corresponding loops 
of the VH domain. This implies that a larger structural repertoire and thus a sufficient diver-
sification in antigen-binding sites can be obtained [9]. More specifically, the introduction of 
additional Cys residues in the CDRs creates extra disulfide bridges within the VHH domain, 
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and these are in part responsible for the diversification of the structural repertoire. The disul-
fide bridges crosslink the antigen-binding loops, resulting not only in the stabilization of the 
domain but also in the induction of constraints in CDR1 or CDR3. These constraints probably 
lead to novel loop conformations and thus in an increase in paratope repertoire. Furthermore, 
VHHs are more prone to insertion and deletion events near or within the paratope compared 
to VHs. This is translated into an increase of the surface area of the hypervariable regions and 
contributes to the structural variation [10].
2. The therapeutic potential of extracellular and intracellular nanobodies
Several monoclonal antibodies (mAbs) have already been approved for clinical use [11], but 
some limitations are still present despite their success. This includes their large size, relative 
instability, which imposes restrictions on the administration route and their relative expense 
of manufacturing. The potential of nanobodies as a therapeutic agent was rapidly recog-
nized as they overcome some of the aforementioned limitations of mAbs. The small size of 
nanobodies in combination with their extended CDR loops allows them to bind into clefts 
and cavities, whereas mAbs preferably recognize flat and concave surfaces. Many biological 
Figure 1. Schematic representation of a conventional IgG antibody and a camelid heavy-chain-only antibody (HCAb). 
For both antibody formats, the smallest producible antibody fragment is depicted: a short-chain variable fragment (ScFv, 
±27 kDa) and a nanobody (Nb, ±15 kDa), respectively.
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interactions take place in clefts, and nanobodies can target these otherwise inaccessible sur-
faces and thus function as neutralizing agents or antagonists of protein-protein interactions. 
More specifically, this property is advantageous when it comes to therapeutically targeting 
infectious diseases since the essential epitopes of pathogens are often hidden. When cancer 
has to be targeted, the small size permits a better tissue penetration and thus a significant 
improvement of the effective antibody concentrations that can be reached in solid tumors. 
Unfortunately, this advantageous property comes with a price. The small size of nanobodies 
results in their rapid clearance from the human body and thus in a limited in vivo half-life 
(a few hours). Therefore, nanobodies are often linked to a serum albumin-binding monomer 
to prolong serum half-life. The monomeric nature of nanobodies simplifies antibody engi-
neering. For instance, nanobodies can be assembled into multimers, thereby increasing their 
potency due to avidity effects. The development of therapy resistance can also be curbed by 
creating bispecific nanobodies. The creation of a targeted drug delivery vehicle is also possible, 
since nanobodies can easily be linked with drugs [12–17]. Additionally, the outstanding sta-
bility of nanobodies under extreme conditions opens the possibility to more patient-friendly 
routes of administration. In general, mAbs are administered via injections, but due to the 
extraordinary stability of nanobodies, they can be administered orally, topically, and even via 
inhalation [15, 18, 19]. The cost of nanobody production lies several times below those of mAb 
production. The fact that nanobodies are efficiently produced in microbial systems keeps the 
expenses low. Considering the fact that immunotherapy involves administration of relatively 
high doses of antibody during prolonged periods, this is a factor that should not be underes-
timated [7, 8, 20]. Currently, there are no nanobody-based products approved as therapeutic 
agent, but several products are in the pipeline or in advanced clinical trials. Their value in 
treating envenoming [21], infections [22], amyloidosis [23, 24], cancer, and other pathologies 
[25, 26] has already been proven. The research concerning the use of nanobodies as a thera-
peutic agent is mainly performed on extracellular targets. Nonetheless, nanobodies can also 
aid in identifying intracellular targets since they directly target a resident, endogenous pro-
tein, similar to how a conventional drug acts. RNAi-based approaches rather eradicate, or at 
least downregulate, expression which is quite different from the mode of action of an average 
drug. Hence, caution is warranted when making predictions regarding the therapeutic value 
of a given protein target using this approach. Moreover, nanobodies retain their functional-
ity in the reducing intracellular environment. The major stumbling block toward a success-
ful clinical implementation however is their inability to traverse the cell membrane. For that 
reason, most experiments are limited to cell cultures and transgenic animals. In the following 
paragraph, the use of nanobodies to target intracellular proteins with possible therapeutic 
implications will be described.
2.1. Intracellular nanobodies and antiviral therapy
2.1.1. Hepatitis
About 500 million people worldwide are chronically infected with hepatitis B virus or hepa-
titis C virus (HBV or HCV). Infection induces an acute and chronic inflammatory liver dis-
ease, which puts the patient at risk of developing liver cirrhosis and possibly hepatocellular 
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carcinoma. Currently, there is no vaccine available against HCV, and there is also no cure 
for most people who are already infected with HBV [27]. Initially, therapy existed of a strict 
and intensive treatment with ribavirin and PEGylated interferon. This regimen was however 
associated with severe side effects [28], emphasizing the importance of further research into 
the pathogenesis of the viruses and how they evade our immune systems. Extensive research 
led to the discovery of direct-acting antivirals (DAAs), which are small compounds targeted 
against viral enzymes. The second-generation DAAs are highly potent in treatment, show 
less side effects, and have a less intensive treatment regimen [29]. However, during infection 
a large number of viral variants are continuously produced, resulting in the presence of quasi 
species within the patient. This heterogeneity implies that not all therapeutic agents will be 
equally effective and that drug resistance may develop. Therefore, the search for other thera-
peutics remains useful. Sarrazin et al. mention that compounds targeting a more conserved 
region of viral proteins have a better chance of efficacy. Importantly, compounds targeting the 
active site of the viral polymerase show a high barrier to the development of resistance, due 
to the fact that mutations at this site often result in loss of polymerase function [30]. As stated 
previously, nanobodies can bind epitopes localized in clefts, like the active site of an enzyme, 
and thus are perfect candidates for antiviral drug development.
The potency of nanobodies for counteracting HCV infection has been evaluated. Several non-
structural HCV proteins have been targeted via nanobodies: NS5B, NS3, NS4A, and NS4B 
[28, 31–33]. NS5B functions as an RNA-dependent RNA polymerase. NS3 has a dual func-
tion and displays serine protease activity in its N-terminal region and helicase activity in its 
C-terminal region. The helicase is involved in the replication of the viral genome and is also 
thought to increase the translational efficiency of the polyprotein by melting highly stable sec-
ondary structures in the HCV RNA [34]. The N-terminal serine protease domain is, together 
with NS4A, involved in downstream processing of the HCV polyprotein with the forma-
tion of mature proteins [32]. NS4B plays a major role in HCV replication by inducing an ER 
membrane web on which HCV replication takes place [31]. Nanobodies against the different 
nonstructural proteins were obtained via screening of a VH/VHH library constructed from 
peripheral blood mononuclear cells of an 8-month-old naïve male dromedary. Recombinant 
nanobodies reduced NS5B activity by two-thirds (ELISA) [28], and NS3 helicase activity was 
inhibited up to 88–100% in the presence of the nanobodies, depending on the assay used 
[33]. Cell-based assays were performed on Huh7 cells (human hepatoma cell line) transfected 
with RNA (genomic replicon of heterologous HCV). The nanobodies also led to a significant 
reduction of HCV RNA levels in Huh7 cells transfected with the JFH1 genotype 2a strain, 
both inside the cells as in the culture medium, when compared to control conditions. Overall, 
the nanobodies were capable of eliciting responses of a magnitude similar as seen for con-
ventional therapeutic strategies (ribavirin + PEGylated interferon or telaprevir) [28, 31–33]. 
Furthermore, treatment of cells with the nanobodies against NS3/NS4A and NS4B induced 
the expression of genes involved in the innate immune response (IRF3, IL28-B, and IFN-β). 
This is interesting because the innate immune response signaling is interrupted by the virus 
[31, 32]. In general, these studies lack a detailed insight into the molecular mechanisms behind 
the observed effects. The authors used computerized modeling to make an assumption about 
which epitopes are recognized by the nanobodies. Crystallization studies would allow a more 
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detailed view and could help to resolve remaining questions. Even more, the crystal struc-
tures could lay the foundation for small molecule development and thus be invaluable. The 
nanobodies certainly have potential, but there are some remaining questions that need to be 
resolved before continuing with animal experiments.
As mentioned earlier, currently the biggest obstacle for using nanobodies as a therapeutic 
against intracellular targets is their inability to traverse cellular membranes. In the afore-
mentioned articles, it was reported that coupling the nanobody with a cell-penetrating pep-
tide (penetratin) seemingly promoted cellular uptake of the nanobody with efficiencies of 
roughly 80% [28]. However, some caution is warranted here, since the mechanisms behind 
the internalization of CPPs are still a matter of debate. Even more, in the highly cited article 
of Richard et al., it has been shown that experiments used to detect the occurrence of CPP 
internalization are sensitive to artifacts. It appeared that even mild fixation protocols used 
for fluorescence imaging can induce an artifactual redistribution of these peptides in the 
nucleus. Furthermore, the highly cationic nature of, for example, penetratin peptides lead 
to their strong binding to the overall negatively charged plasma membrane [35]. It is thus of 
crucial importance to remove membrane-bound peptide before analyzing cellular uptake of 
the construct. Initially, it was thought that CPPs allowed the delivery of biomolecules with-
out relying on endocytosis. Adaptations of the used protocols, however, gave rise to data 
supporting an active process of cellular internalization involving endocytosis. Applications 
with CPPs and the controversial issues regarding their internalization mechanisms are elabo-
rately reviewed and will not be discussed in detail [36, 37]. Internalization via endocytosis is 
however associated with a major drawback, since the delivered biomolecule needs to escape 
from the endosomal vesicles before it traffics back to the plasma membrane for recycling or 
it fuses with lysosomes. This might strongly limit the bioavailability of the compound, thus 
curbing its efficacy. Finally, the nonspecificity of CPP-conjugated constructs imposes a risk of 
drug-induced toxic effects on normal tissues [37]. In conclusion, a meticulous evaluation of 
intracellular uptake of the bioactive molecule and of possible toxic effects on normal tissues is 
warranted, before taking any further steps in its development as a therapeutic agent.
The genome of hepatitis B virus (HBV) is translated into HBV surface proteins, polymerase 
protein, X protein, or core and pre-core proteins [38]. Targeting the hepatitis B surface anti-
gen (HBsAg) and the hepatitis B core antigen (HBcAg) with antiviral drugs to, respectively, 
reduce viral secretion and replication is a feasible strategy. HBsAg is the major component of 
the viral envelope. HBcAg, on the other hand, is the structural unit of the nucleocapsid that 
encloses the viral genome within a viral particle [38, 39].
To obtain nanobodies against the aforementioned proteins, a llama was immunized with 
recombinant HBcAg and HbsAg. The peripheral blood cells and cervical lymph node cells 
were used to construct a VHH library. Both immune and naïve libraries are good sources 
for retrieving antigen-specific binders. However, in general, superior binding affinities are 
observed for nanobodies originating from immune libraries, since they were subjected to 
in vivo affinity maturation. On the other hand, naïve libraries offer an elegant solution for those 
cases where immunization is difficult due to the lack of an antigen, low immunogenicity, or 
toxic antigens [39]. The nanobodies against HBsAg were cloned in frame with an ER-targeting 
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signal and an ER retention signal. Co-transfection of these nanobodies and a HBV-expressing 
plasmid in HepG2 cells induced the intracellular accumulation of HBsAg and caused a reduc-
tion of HbsAg particle secretion of approximately 80–90%. The in vivo potential of the HBsAg 
nanobodies was examined in a SCID mouse. The mouse model for HBV infection was created 
using a hydrodynamics-based transfection method. Remarkably, measured HBsAg levels in 
the plasma decline in the presence of the nanobody, and this reduction goes hand in hand 
with an increase in intracellular HBsAg levels. This observation implies that less virions are 
secreted. The researchers assume that the observed effects are either due to the disruption of 
the interaction between the nucleocapsid and the S-type of viral membrane proteins or due to 
the prevention of the interaction between individual proteins in the ER [40].
2.1.2. HIV
The current anti-HIV treatment strategy, known as highly active antiretroviral therapy 
(HAART), has changed the field and has turned HIV into a chronic manageable disease. 
However, patients are lifelong bound to this regimen, its associated side effects, and drug-
drug interactions. Sometimes, treatment fails due to multidrug resistance which warrants 
research for alternative drugs [41]. Nanobodies could serve as a useful purpose in the treat-
ment of HIV infection and have been successfully raised against Rev and Nef. Rev is involved 
in the nuclear export of late viral mRNA to the cytoplasm. Rev multimers form a higher 
affinity complex with RRE (Rev-response element), and this affinity is a determining factor 
for the efficiency of RNA export [42, 43]. The idea of targeting Nef with antivirals came from 
the observation that a limited amount of patients, infected with Nef-deleted HIV, presented 
a lack of disease progression. The Nef protein exerts multiple functions: CD4 downregula-
tion, major histocompatibility complex downregulation (MHC1), activation of p21-activated 
protein kinase (pak2), and enhancement of virion infectivity. These functions can be targeted 
each independently from one another since the activities are genetically separable. Interfering 
with Nefs’ capacity to downregulate CD4 appears to be the most effective strategy [44].
Vercruysse et al. produced nanobodies against the N-terminal multimerization domain of 
Rev, because its ability to form multimers is essential for its function. One nanobody is capable 
of efficiently inhibiting Rev multimerization in cell-based assays. The nanobody induces a 
cytoplasmic delocalization of Rev. that is similar to that observed for Rev mutants incapable of 
multimerization. In addition, the nanobody is able to suppress the Rev-dependent expression 
of late viral mRNAs and consequently also de novo virus production [42]. Further experi-
ments were performed to elucidate whether the nanobody displays a broad-spectrum anti-
HIV activity. This was examined by infecting several cell lines, expressing the nanobody in 
a stable manner, with different HIV-1 subtypes. Virus replication was monitored 5 days post 
infection by measuring cytopathogenic effects and the presence of virus-associated p24 levels 
in the supernatant. The nanobody strongly reduced p24 levels for infected cells compared to a 
control nanobody. More specifically, p24 levels were reduced by >10 folds for subtype A, > 100 
folds for subtypes C and G, and >10,000 folds for subtypes B, D, and H [45]. The cells proved to 
be resistant to viral replication and survived infection. These results are relevant, considering 
the fact that subtypes A, B, and C are the most prevalent genetic forms on a global scale [46].
Use, Applications and Mechanisms of Intracellular Actions of Camelid VHHs
http://dx.doi.org/10.5772/intechopen.70495
211
Bouchet et al. picked Nef, a HIV-1 nonstructural protein, as target for antiviral therapy. Using 
cell-based assays and in vivo assays, it was established that the Nef-specific nanobody effi-
ciently counteracted Nef-induced CD4 downregulation and p21-activated protein kinase 
(pak2) activation. The functional effects of the nanobody are thought to result from its inter-
ference with the interaction between Nef and other cellular partners [47]. Nef-induced CD4 
downregulation in infected cells is important to prevent interaction between the envelope 
protein (Env) of the budding virion and CD4 of the host cell, since this interaction might 
impede the formation of fully infectious particles [44]. The nanobody is capable of reduc-
ing the rate of Nef-induced CD4 internalization back to levels measured in uninfected cells. 
The biological relevance of this observation was tested in a mouse model (CD4+/HIV Nef Tg 
mouse) that presents a downregulation of cell surface CD4, an altered thymic CD4 T-cell 
development, and a profound peripheral CD4 T-cell depletion. The nanobody rescued the 
Nef-mediated thymic CD4+ T-cell maturation defect and reversed the downregulation of cell 
surface CD4 in vivo. T-cell receptor signaling normally leads to profound actin cytoskeleton 
rearrangements. The Nef-pak2 complex, however, halts these rearrangements by deregulat-
ing cofilin, an actin-severing factor. Actin polymerization in infected T cells is thus strongly 
disturbed. The nanobody disrupts the Nef-Pak2 complex and counteracts as such the inhibi-
tion of actin remodeling in a dose-dependent manner. Finally, it was also observed that the 
inhibition of specific Nef functions by the nanobody resulted in the reduction of virus infec-
tivity of new progeny virions by 80% (molar ratio of 1:1) [47].
Current HAART targets four different steps in the HIV-1 replication circle: the conversion 
of viral genomic RNA into dsDNA, the maturation of budding viral particles, the entry of 
the virus into new target cells, and the insertion of viral DNA into a host cell chromosome. 
Although current strategy is effective, it remains important to explore novel treatment strat-
egies. The development of compounds that inhibit less explored drug targets would be of 
benefit, and structural biology can aid in defining new drug targets [48]. Nanobodies tar-
geted against both Rev. and Nef appear to have pronounced effects on pathogeny of HIV-1. 
Crystallization studies to elucidate the exact binding epitopes for both nanobodies are thus of 
paramount importance since they could aid in new small compound design.
2.2. Intracellular nanobodies as a means to suppress toxins
There exists a multitude of antimicrobial drugs, but compounds capable of neutralizing the 
produced toxins are often lacking. The question whether or not antibodies hold great poten-
tial as toxin-neutralizing agents has been investigated by several researchers. Examples of 
studies where monoclonal antibodies are used as antitoxins are listed in the review of Chow 
et al. [49]. Several researchers have exploited nanobodies as a means to neutralize toxins. 
Intrabodies have been employed to counteract following toxins: ricin, Salmonella SpvB pro-
tein, and botulinum neurotoxin.
2.2.1. Ricin
Ricin is a naturally occurring toxin derived from the castor bean plant and a well-known 
type 2 ribosome-inactivating protein. It achieves an inhibition of eukaryotic ribosomes by the 
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depurination of a specific adenine in the 28S ribosome resulting in cell death. Exposure might 
be lethal, and unfortunately current treatments are mainly of a symptomatic and supportive 
nature [50]. Herrera et al. constructed a bispecific nanobody, named JJX12, consisting of a 
VHH targeted against the enzymatic subunit of ricin coupled with a VHH targeted against 
the galactose-binding subunit [51]. JJX12 fully protects mice against a ricin challenge (molar 
ratio of 4:1). The protective effects observed for the bispecific construct are superior to those 
observed for an equimolar mixture of the nanobodies and are the result of both extracellu-
lar and intracellular effects. JJX12 promotes aggregation of ricin in solution and makes cell-
bound ricin-JJX12 complexes more resistant to dissociation as shown by ricin competition 
assays with lactose [51]. In the presence of these complexes, further ricin binding to the cell 
surface is reduced by shielding cell surface receptors for the galactose-binding subunit of ricin 
[52]. The presence of aggregates changes the internalization and intracellular trafficking of 
ricin. Internalization of the aggregates occurs via a macropinocytosis-like mechanism rather 
than via receptor-mediated clathrin-dependent and clathrin-independent endocytosis, which 
is normally observed for ricin. Furthermore, biochemical and live cell imaging techniques 
showed a 54% reduction of the retrograde transport of ricin to the trans-Golgi network and 
the accumulation of ricin in late endosomes in the presence of JJX12, which probably targets 
ricin for degradation [51].
2.2.2. Salmonella SpvB protein
Salmonella bacteria are Gram-negative enterobacteria associated with human enteric fever. 
The systemic virulence of the bacterium is largely dependent on the SpvB gene, encoding an 
actin ADP-ribosylating toxin that is secreted into the host cell cytosol. The toxin interferes 
with actin polymerization resulting in apoptotic cell death. Nanobodies targeted against the 
SpvB protein are capable of blocking its enzymatic and cytopathic effects. By means of in vitro 
radioactivity and fluorescence assays, it was demonstrated that the nanobody completely res-
cues actin polymerization from the inhibitory effects of the SpvB toxin at a molar ratio of 1:1. 
Cell-based assays, performed on RAW macrophages and Vero cells, confirmed these observa-
tions, since cells exposed to the toxin presented no signs of cell rounding or actin cytoskeleton 
disintegration in the presence of the nanobody [53].
2.2.3. BoNTs
Botulinum neurotoxins (BoNTs) produced by the Gram-positive bacterium Clostridium botu-
linum can cause flaccid paralysis in humans, which can last for several months. The toxins 
deliver their light chain, possessing a protease function, to the motor neurons. The protease 
cleaves SNARE proteins and as such prevents the release of acetylcholine from presynap-
tic nerve terminals at the neuromuscular junction causing a neuromuscular blockade [54, 
55]. Two different strategies were used to suppress botulinum neurotoxin intoxication. 
Tremblay et al. investigated the potential of using nanobodies as a protease inhibitor per 
se [55], whereas Kuo et al. implemented the nanobody as a part of a targeted F-box agent 
to induce accelerated degradation of the protease [54]. A nanobody with nanomolar affin-
ity (Kd  ̴ 1 nM) for the light chain of BoNT serotype A (A-Lc) was used for both strategies. 
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Serotype A is associated with the longest persistence and is thus most relevant for therapeu-
tic intervention. The nanobody allows a near stoichiometric inhibition of BoNT-A function 
as shown by an in vitro FRET-based SNAP25 cleavage assay [55]. The production of cells 
expressing the nanobody in a stable manner could offer an elegant solution to problems 
associated with transient transfection techniques and was consequently implemented in the 
studies performed with the targeted F-box reagent.
Kuo et al. made a fusion protein between a nanobody and a truncated F-Box protein (TrCP) 
that is capable of associating with Skp1 and Cullin1, with the formation of the SCF com-
plex. This complex, called targeted F-box (TFB), functions as an E3 ubiquitin ligase, thus tar-
geting BoNT proteases for proteasomal degradation. Two constructs were made in which a 
nanobody targeted against either A-Lc or B-Lc was incorporated. The TFB fusion proteins 
reduce A-Lc and B-Lc levels with 65 and 50%, respectively (capture ELISA experiments), and 
decrease the half-life of the A-Lc protease (from  ̴3.7 to  ̴1.5 days). Application of MG132, a 
proteasome inhibitor, results in the accumulation of poly-ubiquitinylated BoNT protease and 
eliminates the effect of the TFB fusion proteins on its steady-state levels. This indicates that 
the observed effects are due to the increased degradation of the BoNT protease. Furthermore, 
in the presence of the TFB fusion proteins, cells are less sensitive to BoNT-A intoxication and 
also recover 2.5 times faster [54].
2.3. Camelid intrabodies: a ministering angel for patients suffering from protein 
misfolding diseases?
Proteins exert crucial roles in a variety of cellular processes. Each of these proteins has to 
adopt its native tridimensional structure to acquire the functional biological state and thus 
to act faultlessly. However, sometimes proteins fail to either fold correctly or to maintain the 
native state due to the presence of mutations or increased protein levels. When these proteins 
escape the inherent quality control systems, serious diseases can develop. These disorders can 
be characterized by the deposition of misfolded peptides or proteins in the nervous system or 
other tissues and organs resulting in pathological and insoluble aggregates.
Preventive and curative treatments are often lacking. These therapeutic approaches are fea-
sible when using nanobodies as a tool: increasing the stability of the correctly folded proteins, 
neutralization of toxic protein/peptide species, and inhibiting or reversing the aggregation 
of misfolded proteins into oligomers or fibrils [56]. Several research groups have already 
exploited the use of nanobodies for targeting protein misfolding diseases [57–59]; however, 
most of the time, they aim at extracellular targets. We will focus on the intracellular applica-
tion of nanobodies.
2.3.1. Oculopharyngeal muscular dystrophy
Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant disease character-
ized by an extended N-terminal poly-alanine stretch of polyadenylate-binding protein nuclear 
1 (PABPN1). The poly-alanine stretch is extended from 10 to 12–17 alanines. The mutant protein 
forms aggregates in skeletal muscles, and this phenomenon is, at least in part, responsible for 
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the disease, although the exact pathological mechanisms are still poorly understood. PABPN1 
is a multifunctional protein and is involved in pre-mRNA polyadenylation, transcription regu-
lation, and mRNA nucleocytoplasmic transport [56].
Verheesen et al. screened a nonimmune VHH library for PABPN1-selective binders. Panning 
yielded six nanobodies with affinities ranging between 5 and 57 nM. Initial experiments were 
performed with nanobody 3F5 (Kd = 5 nM), which binds PABPN1 at its N-terminal coiled-
coiled domain. Co-transfection of mutant PABPN1 and nuclear targeted 3F5 (3F5-NLS) in 
HeLa and COS cells showed a dose-dependent reduction in the formation of aggregates 
(37% → 10% in HeLa cells, P < 0.01). The expression of the nanobody neither induces cyto-
toxic effects (MTT assay) nor has any effects on mutant PABPN1 expression levels [60]. A 
more in-depth analysis on how the formation of intranuclear inclusions is prevented revealed 
that the nanobody reduces the formation of oligomers of mutant PABPN1 but not of insoluble 
aggregates [61]. The in vivo efficiency of the six nanobodies was tested in a Drosophila model 
of OPMD in which the expression of mutant PABN1 and the nuclear targeted nanobodies 
is induced with the muscle-specific driver Mhc-Gal4. Nanobody 3F5-NLS showed the best 
in vivo efficacy and alleviated several symptoms of OPMD in the Drosophila model, includ-
ing prevention of degenerative effects on flight muscles and the restoration of muscle fiber 
ultrastructure (Z and M bands). Transcriptome analysis performed to evaluate thorax gene 
expression patterns demonstrated that 3F5-NLS induced a partial or complete rescue of 58% 
of the genes deregulated by the presence of mutant PABPN1. These effects are the strongest 
in the early stages (day 2 after induction) but persist during the life span [62].
2.3.2. Gelsolin amyloidosis
Gelsolin amyloidosis is an autosomal dominant disease for which currently only symptom-
atic treatment strategies exist. A point mutation in the GSN gene (G654 A/T) is responsible 
for the incorrect folding of the secondary domain of mutant gelsolin (D187 N/Y) that adopts 
a protease-sensitive conformational state. A pathological proteolytic cascade involving furin 
and MT1-MMP like proteases leads to the secretion of amyloidogenic 8 and 5 kDa peptides in 
the extracellular matrix and thus to the formation of extracellular deposits [63]. Van Overbeke 
et al. used gelsolin nanobodies to shield mutant plasma gelsolin (PG) from aberrant furin 
cleavage [24]. Furin is a membrane-associated pro-protein convertase that is ubiquitously 
expressed. It cleaves mutant PG as it passes through the trans-Golgi network (TGN) and gen-
erates a C-terminal 68 kDa fragment (C68) that is secreted into the extracellular matrix [63]. 
This initial step in the amyloidogenic cascade is targeted using a Nb that binds mutant PG 
near the furin cleavage site with low nanomolar affinity (10 nM, in the presence of Ca2+). In 
vitro experiments demonstrated a dose-dependent decrease of mutant PG cleavage. The C68 
signal intensity is reduced by 76% (P < 0.001) when a twofold molar excess of Nb is added. 
In cell-based assays, the nanobody drastically reduced secretion of C68 in the cell medium. 
The in vivo efficiency of the nanobody was further analyzed in a gelsolin amyloidosis/nano-
body double-positive mouse model expressing human mutant PG. The Nb not only positively 
affects transgenic mutant gelsolin proteostasis in skeletal muscle tissue but also attenuates the 
decrease in contraction speed of the extensor digitorum longus in an 8-min fatigue protocol 
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[24]. Using adeno-associated virus as a vehicle, a bispecific nanobody was introduced in these 
mice that protects against both furin and MT1-MMP, yielding similar effects on muscle con-
traction speed [64, 65]. Inhibiting the enzymatic activity of furin could be an alternative strat-
egy, and noncompetitive furin-inhibiting nanobodies have been identified although they have 
not been tested for treatment of gelsolin amyloidosis [66]. However, despite the involvement 
of furin in several pathological processes, some considerations have to be made regarding its 
use as a therapeutic target. Although a complete/partial cleavage redundancy of furin toward 
several substrates was observed in the liver of an interferon-inducible Mx-Cre/loxP, furin 
knockout mouse model and obvious adverse effect were absent; a complete knockout of furin 
in a mouse model resulted in embryonic lethality at day 11 [67, 68]. This observation probably 
precludes their use in chronic treatments because it is rather unlikely that the long-term inhibi-
tion of furin does not go hand in hand with severe adverse effects. Therefore, shielding mutant 
PG from aberrant cleavage seems to be the better strategy. Moreover, this approach is already 
successfully implemented in the treatment of early-stage familial amyloid polyneuropathy 
caused by amyloidogenic variants of transthyretin, thus highlighting its feasibility [69].
3. Camelid intrabodies: a versatile research tool
Over the years, nanobodies have earned their mark as a research tool. A variety of extracel-
lular and intracellular applications using nanobodies exist, and the latter will be discussed 
here. Intrabodies are often used to unravel protein functions and to gain insight into their 
dynamics. The versatility of nanobodies and the ease by which they can be engineered allow 
researchers to use different lines of approach (Figure 2). Chromobodies, consisting of a nano-
body fused with a fluorescent protein, allow researchers to recognize and trace endogenous 
proteins in living cells [70]. Since they are already well known, they will not be discussed in 
detail here.
3.1. Pinpointing protein functions
Nanobodies are an attractive tool for the determination of endogenous protein function. They 
not only complement well-known RNAi and CRISPR/Cas9 techniques but also allow a more 
detailed insight by pinpointing specific functions with “surgical precision” by targeting indi-
vidual protein domains (rather than eliminating the entire protein altogether) and protein 
conformations, which cannot be achieved by expression modulation. In other words, nano-
bodies can be of inestimable value to deepen our knowledge of several biological pathways. 
Researchers have employed several strategies for assessing the functionality of proteins or 
protein domains, and the different options will be discussed here.
As stated earlier, nanobody cDNAs are available, and these are easily engineered. This implies 
that the addition of a delocalization tag is fairly straightforward. A variety of targeting sequences 
are available and can be used to induce the enrichment of both nanobody and its target at spe-
cific (ectopic) subcellular compartments. This strategy allows researchers to assess the interac-
tion between the nanobody and its target in the strongly reducing intracellular environment 
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and thus to confirm the in vivo functionality of nanobodies. Moreover, in this way, one can also 
disturb protein function by restricting free diffusion of the protein and limiting its availability 
at places where it is needed [71]. Considering that the paratope of the nanobody is located at 
its N-terminal end, it is safer to fuse the tag at the C-terminal end of the nanobody. Otherwise, 
a substantial risk at disturbing antigen binding exists [2], although there are examples where a 
long tag is added to the nanobody N-terminus without disturbing its functionality [72]. Beghein 
et al. elegantly demonstrated how effectively nanobodies can delocalize their target protein to a 
variety of subcellular organelles. A survivin Nb (Kd ~ 1 nM) was capable of guiding endogenous 
survivin in or out the nucleus (nuclear localization sequence tag and nuclear export sequence tag), 
capturing survivin on the outer membrane of mitochondria (mitochondrial outer membrane tag) 
and even at the intermembrane area (mitofilin tag) which probably required (partial) unfolding 
of the nanobody and possibly chaperone-assisted entry into mitochondria. This had not yet 
been investigated. Also, transport of survivin in the peroxisomes (PST-1 tag) was demonstrated 
[72]. Since interaction between the nanobody and survivin apparently did not perturb survivin 
functionality, the tagged nanobody is a perfect research tool for further elucidating survivin 
biology. This strategy also provided evidence that only actin-free gelsolin is able to migrate to 
the nucleus (in contrast to the actin-gelsolin complex) to potentially act as a nuclear cofactor for 
Figure 2. Schematic overview of nanobody-based applications in research. Upper panel. Left: Nanobodies can be 
equipped with a delocalization signal sequence, which allows the enrichment of a protein of interest (POI) at a specific 
subcellular localization, such as mitochondria. Middle: Nanobodies can exert a direct inhibitory effect which induces 
a protein knockout. Right: Nanobodies can be used to target a POI for proteasomal degradation. For this purpose, the 
nanobody is fused with a cullin-RING E3 ubiquitin ligase. Lower panel. Left: A chromobody, consisting of a fusion 
between a nanobody and a fluorescent protein (FP), allows the visualization and tracing of endogenous proteins in a 
background of contaminating proteins. Right: This nanobody-based application allows one to determine whether or not 
two proteins of interest interact. Both proteins are labeled with a different fluorophore. One protein, labeled with GFP, 
is recruited to a specific location via a GFP Nb coupled with a targeting signal. If the second protein, in this example 
labeled with RFP, is an interaction partner, both fluorescent signals will co-localize. When a compound interferes with a 
specific protein-protein interaction, the co-localization is absent.
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the androgen receptor [73], that fascin plays a role in the formation of filopodia/cell spreading 
and is also involved in MMP9 secretion, and that the SH3 domain of cortactin directly regulates 
MMP secretion [74].
Some nanobodies exert a direct inhibitory effect, resulting in a functional knockout of the pro-
tein. These nanobodies can help researchers to define the biochemical activities of proteins. 
For example, mechanistic insights in podosome formation were revealed by two inhibitory 
nanobodies targeted against L-plastin (LPL). LPL Nb5 is capable of blocking the actin-bun-
dling activity of L-plastin, and LPL-Nb9 locks LPL in an inactive conformation. Experiments 
involving these nanobodies revealed the participation of L-plastin (LPL) in podosome forma-
tion and stability [75]. Furthermore, L-plastin is a component of cancer cell invadopodia and 
contributes to matrix degradation and cancer cell invasion. These effects are mediated by the 
actin-bundling activity of L-plastin and its bundling independent role in MMP9 secretion and 
activity, as revealed by the differential effects observed in the presence of LPL Nb5 and LPL 
Nb9 [76]. One can also interfere with signaling pathways by specific inhibition of the transcrip-
tional activity of proteins, like beta-catenin and p53 [77, 78]. These nanobodies can be used to 
elucidate the impact of cofactors and post-translational modifications on the targeted protein 
and allow us to broaden our understanding of the respective signaling pathways. Insight into 
pathological mechanisms, which might result in the identification of druggable targets, can 
also be obtained. For example, nanobodies were used to investigate the role of two enzymatic 
domains of TcdB, a toxin produced by Clostridium difficile. Using specific inhibition of the effec-
tor glycosyltransferase activity or the cysteine protease, it was, among other things, established 
that the TcdB-cytopathic effects are mainly mediated by the glycosyltransferase activity [79].
Finally, nanobodies are known to stabilize certain protein conformations and are often used 
as an aid in crystallization experiments [2]. This property also comes in handy when one 
wants to study the mechanisms by which cellular receptors translate extracellular cues into 
intracellular responses. Depending on which conformation the receptor adopts after ligand 
binding, certain downstream signaling events can be either activated or inhibited. Staus 
et al. have identified nanobodies that preferentially recognize and stabilize the β2 adrenergic 
receptor in its active or inactive conformation resulting in a variety of functional effects [80]. 
These experiments indicate that nanobodies, by acting as an allosteric modulator of receptors, 
can help us to understand receptor biology.
3.2. Depleting endogenous proteins through proteasomal targeting
An alternative way to determine the function of a protein of interest (POI) in an in vivo set-
ting is to selectively induce their degradation and study the resulting knockout phenotype. To 
achieve this goal, three different groups have exploited a combination of nanobodies and the 
endogenous ubiquitin proteasome pathway, a system that is responsible for selective protein 
degradation in eukaryotes [81–83]. Caussinus et al. were the first to use the ubiquitin pathway 
for targeted degradation by making adaptations of an E3 ubiquitin ligase, more specifically the 
cullin-RING 1 (CLR1) E3 ligase complex. For this purpose, a fusion between the F-box domain 
of Slmb and a GFP Nb (VHH GFP4) was made. Slmb is part of an F-box protein, responsible 
for substrate recognition that is expressed in Drosophila melanogaster. When this construct, 
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called DeGradFP, was expressed in mammalian cells or D. melanogaster embryos, certain GFP-
tagged proteins were depleted. DeGradFP was also capable of phenocopying specific loss of 
function mutations. In spite of these successful results, treatment with DeGradFP was not 
always followed by the degradation of the targeted protein (e.g., GFP) [81]. In addition to that, 
a broader application of DeGradFP is still to be demonstrated.
Just like DeGradFP, the cullin-RING E3 ubiquitin ligases were used as the framework for 
synthetic E3 ligase design. In an attempt to enhance the E3 activity, however, the GFP Nb 
was fused directly to a truncated adaptor protein instead of the substrate recognition pro-
tein. The best results were obtained with Ab-SPOP, a synthetic version of the CLR3 E3 ligase 
complex, displaying a 10-fold stronger signal reduction of a GFP-tagged protein compared 
to DeGradFP (50-fold vs. 5-fold). Importantly, the construct degrades only nuclear proteins, 
and possibly in the future, similar constructs may become available that degrade cytoplas-
mic proteins. The in vivo effectiveness of Ab-SPOP was confirmed in zebra fish embryos. 
Ab-SPOP-induced depletion of Hmg2a-citrine, a protein responsible for the modulation of 
nucleosome and chromatin structure, resulted in various early developmental defects [83]. 
Fulcher et al. tailored the von Hippel-Lindau (VHL) protein as an affinity-directed protein 
missile, called AdPROM. Under normoxic conditions, this substrate recognition protein 
recruits the hypoxia-inducible factor (HIF1α) to the CLR2 E3 ligase. AdPROM is composed of 
a fusion between the VHL protein and a GFP Nb. It was of crucial importance that the GFP Nb 
was positioned at the C-terminus of the VHL protein in order to obtain a proper orientation of 
the target proteins to the CLR2 E3 ligase complex. Since the paratope of a nanobody is local-
ized at the N-terminal end, one should definitely check for potential detrimental effects of this 
fusion on the binding capacity of the nanobody itself. However, the affinity-directed protein 
missile was competent in inducing the specific degradation of GFP-tagged VPS34 and PAWS1 
proteins in human cell lines, which was further substantiated by the observation of functional 
effects. Interestingly, during these experiments the researchers observed the co-degradation 
of UVRAG which is a regulatory component of the VPS34 kinase complex. This suggests that 
AdPROM has the potential of destroying protein complexes although only individual pro-
teins are targeted [82]. Targeted degradation of proteins of interest by the use of nanobodies 
holds great potential and might be the perfect complement to CRISPR/Cas systems or RNAi 
in the elucidation of protein function. The tunability of this system is a huge benefit. Future 
experiments should point out whether the GFP Nb can be replaced by highly selective nano-
bodies targeted against specific proteins. In this way, one could investigate the functions of 
the protein of interest in a more direct manner, without the requirement of protein tags.
3.3. Detection of protein-protein interactions
Nanobodies can be utilized for the detection of protein-protein interactions in cell-based 
assays. There is a large supply of in vitro methods which can be used for the detection of 
protein-protein interactions. These methods are widely used and highly efficient for high-
throughput screenings but are limited by the fact that they don’t operate in intact mamma-
lian cells. Screening for interaction between proteins in their native environment guarantees 
their proper folding and the presence of necessary cofactors or regulatory proteins. Both 
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 nanobody-based methods rely on the interaction between a GFP Nb and a GFP-tagged pro-
tein. Herce et al. covalently linked a GFP Nb with a protein that accumulates at a specific 
subcellular location. In mammalian cells, this protein could be, for example, laminin B1 or 
centrin, which results in the delocalization of the GFP Nb to the nuclear lamina or the cyto-
plasmic centrioles, respectively. Subsequently, a GFP-tagged protein will be recruited to a 
specific location. If the second protein of interest, labeled with another fluorophore, interacts 
with the first protein of interest, the fluorophores will co-localize at a discrete spot. This inter-
action can be visualized by a single-fluorescence snapshot. Interestingly, this technique also 
allows screening for inhibitors of protein-protein interactions [84]. Another recently devel-
oped technique uses biocompatible engineered upconversion nanoparticles (UCNPs) conju-
gated with GFP Nbs. Visualization of the interaction between two proteins of interest is based 
on the lanthanide resonance energy transfer (LRET). As a proof of concept, they probed for 
the indirect interaction between the mitochondrial proteins TOM20 and TOM7. The latter was 
expressed as a fusion protein with EGFP and the former as a fusion protein with dsRed and a 
Halo tag. This Halo tag was subsequently labeled with tetramethylrhodamine (TMR), while 
the EGFP was recognized by the GFP Nb-labeled UCNPs. Co-localization of both proteins 
results in the detection of LRET-sensitized TMR emission. Remarkably, TOM7 and TOM20 
are spatially separated by TOM40. The capacity of this technique for reporting indirect long-
distance interactions might be of interest to unravel cellular protein complexes [85].
4. Concluding remarks
Nanobodies are highly versatile tools with interesting biochemical properties, which result 
in their application in various fields ranging from basic research and diagnostics to therapy. 
In this chapter, we aim to shed light on their multifunctionality and in this way encourage 
other researchers to include this technology in their future projects. Since their discovery in 
1993, the numbers of publications wherein nanobodies are employed are gradually increas-
ing which indicate that their merit has been proved. Here, we have shown that nanobodies 
have a high therapeutic potential and form an ideal stepping stone to drug development. 
Despite isolated cases, nanobodies are not capable of traversing the cellular membrane, 
preventing their direct use as a therapeutic. The effects observed with nanobody treat-
ment are established through multiple mechanisms. Nanobodies can act as an inhibitor of 
enzymatic activity, interfere with specific protein-protein interactions, and shield a protein 
of interest from aberrant cleavage, or they can be used as a tool to target proteins for pro-
teasomal degradation. We believe that effects triggered by nanobodies in vitro or in vivo 
are a faithful representation of what to expect with conventional pharmacological drugs, 
since both compounds directly target the resident endogenous protein. However, since cur-
rent experiments are often limited to cell-based assays, animal experiments are warranted 
to confirm their effectiveness. Furthermore, nanobodies have a lot to offer as a research 
tool. They can help researchers to elucidate protein functions and thereby gain insight in 
biological pathways. Several strategies are possible, ranging from subcellular delocaliza-
tion to the induction of protein knockouts. Last but not least, nanobodies may represent an 
adequate answer to problems encountered with (conventional) antibody reproducibility 
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[86, 87]. Indeed, particularly polyclonal antibodies run out of stock at some point in the 
future, making experimental verification impossible. Because nanobody cDNAs are read-
ily obtained and researchers all over the world can use exactly the same nanobody in their 
experiments, problems of reproducibility can be reduced. In the future, we hope to stimu-
late a closer consultation within the nanobody field and by doing so taking the research to 
the next level.
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